메뉴 건너뛰기
The Lancet Oncology
Volumn 11, Issue 2, 2010, Pages 104-105
Targeting the target: a step forward for the treatment of non-small-cell lung cancer
Author keywords

[No Author keywords available]
Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR;
EID: 75249102138     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70390-0     Document Type: Letter
Times cited : (4)
References (6)
  • 1
    • 75249087060 scopus 로고    scopus 로고
    • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
    • Mitsudomi T., Morita S., Yatabe Y., et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11 (2010) 121-128
    • (2010) Lancet Oncol , vol.11 , pp. 121-128
    • Mitsudomi, T.1    Morita, S.2    Yatabe, Y.3
  • 2
    • 70350493524 scopus 로고    scopus 로고
    • First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts): a phase III study (002) by North East Japan Gefitinib Study Group
    • Kobayashi K., Inoue A., Maemondo M., et al. First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts): a phase III study (002) by North East Japan Gefitinib Study Group. Proc Am Soc Clin Oncol 27 suppl (2009) 15s
    • (2009) Proc Am Soc Clin Oncol , vol.27 , Issue.SUPPL
    • Kobayashi, K.1    Inoue, A.2    Maemondo, M.3
  • 3
    • 22044445517 scopus 로고    scopus 로고
    • Erlotinib in previously treated non-small-cell lung cancer
    • Shepherd F.A., Pereira J.R., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353 (2005) 132-232
    • (2005) N Engl J Med , vol.353 , pp. 132-232
    • Shepherd, F.A.1    Pereira, J.R.2    Ciuleanu, T.3
  • 4
    • 56249109644 scopus 로고    scopus 로고
    • Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
    • Kim E.S., Hirsh V., Socinski A.A., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372 (2008) 1809-1818
    • (2008) Lancet , vol.372 , pp. 1809-1818
    • Kim, E.S.1    Hirsh, V.2    Socinski, A.A.3
  • 5
    • 69949162760 scopus 로고    scopus 로고
    • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    • Mok T.S., Wu Y.-L., Thongprasert S., et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361 (2009) 947-957
    • (2009) N Engl J Med , vol.361 , pp. 947-957
    • Mok, T.S.1    Wu, Y.-L.2    Thongprasert, S.3
  • 6
    • 69949186250 scopus 로고    scopus 로고
    • Screening for epidermal growth factor receptor mutations in lung cancer
    • Rosell R., Moran T., Queralt C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361 (2009) 958-967
    • (2009) N Engl J Med , vol.361 , pp. 958-967
    • Rosell, R.1    Moran, T.2    Queralt, C.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.